120074-75-1

Upstream product

• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 538-75-0 dicyclohexyl-carbodiimide 

Downstream Products

• 1260369-55-8 C₄₇H₇₇N₉O₁₁ 
• 1260369-54-7 C₄₅H₇₃N₉O₁₁ 
• 1260369-53-6 C₄₆H₇₅N₉O₁₁ 
• 1260369-65-0 C₄₇H₇₉N₉O₁₂ 
• 1260369-64-9 C₄₅H₇₅N₉O₁₂ 
• 1260369-63-8 C₄₆H₇₇N₉O₁₂ 
• 300695-76-5 7-(N-t-butyloxycarbonyl-β-alanyloxy)-5-hydroxy-2-phenylchromen-4-one 
• 652158-82-2 ethyl 5-(2-((tert-butoxycarbonyl)amino)ethyl)-1,2,4-oxadiazole-3-carboxylate 

Relevant academic research and scientific papers

Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates

Disclosed are efficient and scalable processes for preparing 1,2,4- and 1,3,4-oxadiazole carboxylates from readily available starting materials.

Ophthalmic liposomes

A liposome composition with enhanced retention on ocular surfaces, for use in ophthalmic drug delivery and dry eye treatment. The liposomes contain about 10-40 mole percent of an amine-derivatized lipid component in which a charged amine group is spaced from a lipid polar head region by a carbon-containing spacer arm at least 3 atoms in length. The liposomes preferably have a close packed lipid structure produced by inclusion of between 20-50 mole percent of cholesterol or an amine-derivatized cholesterol, and/or phospholipids with predominantly saturated acyl chain moieties. The liposomes may be suspended in an aqueous medium containing a high-viscosity polymer, formulated in paste form, or embedded in a polymer matrix, to enhance further the retention of liposomes on a corneal surface.